Elevation Oncology Plans To Expand Its Ongoing Phase 1 Trial To Include Two Combination Cohorts Evaluating EO-3021 For Advanced Gastric Or Gastroesophageal Junction Cancer. The Company Expects To Initiate Dosing In Combination Portion By Year-end 2024
Portfolio Pulse from Benzinga Newsdesk
Elevation Oncology plans to expand its Phase 1 trial to include two combination cohorts evaluating EO-3021 for advanced gastric or gastroesophageal junction cancer. The company expects to initiate dosing by the end of 2024, following clinical supply agreements with Eli Lilly and GSK.
June 27, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology is expanding its Phase 1 trial to include two combination cohorts for EO-3021, targeting advanced gastric or gastroesophageal junction cancer. The company has signed clinical supply agreements with Eli Lilly and GSK, and plans to start dosing by the end of 2024.
The expansion of the Phase 1 trial and the clinical supply agreements with major pharmaceutical companies Eli Lilly and GSK are positive developments for Elevation Oncology. These steps indicate progress in their research and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
GSK has signed a clinical supply agreement with Elevation Oncology to provide dostarlimab for a Phase 1 trial evaluating EO-3021 in combination for advanced gastric cancer.
The clinical supply agreement with Elevation Oncology underscores GSK's commitment to advancing cancer treatments, potentially boosting its market position and future revenue from successful trials.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Eli Lilly has signed a clinical supply agreement with Elevation Oncology to provide ramucirumab for a Phase 1 trial evaluating EO-3021 in combination for advanced gastric cancer.
The clinical supply agreement with Elevation Oncology highlights Eli Lilly's involvement in innovative cancer treatments, which could enhance its reputation and future revenue from successful trials.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50